• 1638 Citations
  • 26 h-Index
20002020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 1997-2003 Ph.D., Department and Graduate Institute of Pharmacology, National Taiwan University
  • 1993-1997 B.S., School of Pharmacy, Taipei Medical University

Experience

  • 2020.08- Director, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
  • 2015.08- Professor, Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University
  • 2015.08- Professor, Graduate Institute of Medical Sciences, Taipei Medical University
  • 2011.08-2015.07 Associate Professor, Department of Pharmacology, School of Medicine, Taipei Medical University
  • 2007.08- Assistant Professor, Graduate Institute of Medical Sciences, Taipei Medical University
  • 2007.08-2011.07 Assistant Professor, Department of Pharmacology, School of Medicine, Taipei Medical University
  • 2006.08-2007.07 Assistant Professor, School of Medicine, Taipei Medical University
  • 2003.11-2006.07 Postdoctoral Researcher, School of Medicine, Taipei Medical University

Research Interests

  • Molecular Pharmacology, Angiogenesis, Signal transduction

Fingerprint Dive into the research topics where Ming-Jen Hsu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

新穎性長鏈烴基醯胺WMJ化合物之抗發炎作用評估與藥理機轉探討

Hsu, M.

3/1/202/1/21

Project: C - Project of Allianceo - Chi Mei Medical Center

探討支架蛋白shank3參與TNF-α誘導腦部內皮細胞表現VCAM-1的作用機轉

Hsu, M.

7/1/192/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

新穎性烴基醯胺衍生物WMJ-F-16之抗發炎作用機轉探討

Hsu, M.

7/1/192/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output

  • 1638 Citations
  • 26 h-Index
  • 59 Article
  • 1 Poster
  • 1 Review article

Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade

Huang, S. W., Chyuan, I. T., Shiue, C., Yu, M. C., Hsu, Y. F. & Hsu, M. J., Jan 1 2020, In : Journal of Cellular and Molecular Medicine. 24, 2, p. 1822-1836 15 p.

Research output: Contribution to journalArticle

Open Access
  • 3 Citations (Scopus)

    A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling

    Lien, J. C., Chung, C. L., Huang, T. F., Chang, T. C., Chen, K. C., Gao, G. Y., Hsu, M. J. & Huang, S. W., Oct 1 2019, In : British Journal of Pharmacology. 176, 20, p. 4034-4049 16 p.

    Research output: Contribution to journalArticle

  • WMJ-S-001, a Novel Aliphatic Hydroxamate-Based Compound, Suppresses Lymphangiogenesis Through p38mapk-p53-survivin Signaling Cascade

    Huang, S. W., Yang, H. Y., Huang, W. J., Chen, W. C., Yu, M. C., Wang, S. W., Hsu, Y. F. & Hsu, M. J., Nov 6 2019, In : Frontiers in Oncology. 9, 1188.

    Research output: Contribution to journalArticle

    Open Access
  • A novel hydroxamate-based compound WMJ-J-09 causes head and neck squamous cell carcinoma cell death via LKB1-AMPK-p38MAPK-p63-survivin cascade

    Yen, C. S., Choy, C. S., Huang, W. J., Huang, S. W., Lai, P. Y., Yu, M. C., Shiue, C., Hsu, Y. F. & Hsu, M. J., Mar 1 2018, In : Frontiers in Pharmacology. 9, MAR, p. 1-17 17 p., 167.

    Research output: Contribution to journalArticle

  • 2 Citations (Scopus)

    CME-1, a novel polysaccharide, suppresses iNOS expression in lipopolysaccharide-stimulated macrophages through ceramide-initiated protein phosphatase 2A activation

    Sheu, J. R., Chen, Z. C., Hsu, M. J., Wang, S. H., Jung, K. W., Wu, W. F., Pan, S. H., Teng, R. D., Yang, C. H. & Hsieh, C. Y., Feb 1 2018, In : Journal of Cellular and Molecular Medicine. 22, 2, p. 999-1013 15 p.

    Research output: Contribution to journalArticle

  • 9 Citations (Scopus)